Impressively, the AZD5991-venetoclax combination significantly reduced both the subcutaneous tumor burden and decreased the β2M levels (Fig. 6B, C) as compared with both single treatment groups (n = 5, p = 0.0002 for AZD5991, p = 0.0191 for venetoclax), showing the superior in vivo anti-tumor activity of the combination. The gene discussed is B2M; the disease is neoplasm.